For instance, in AML-09, we observed a selection of a small subclone with FLT3 p.D835Y during azacitidine and sorafenib (a FLT3 inhibitor) treatment, which was associated with relapse (Fig. 6). The gene discussed is FLT3; the disease is acute myeloid leukemia.